( NASDAQ-NMS:ARRY,NASDAQ-NMS:ONTY )

News from oncothyreon inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 18, 2014, 08:45 ET Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock

SEATTLE, Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the pricing of previously announced concurrent but separate...


Sep 17, 2014, 16:05 ET Oncothyreon Announces Proposed Public Offerings

SEATTLE, WA, Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced that it intends to offer and sell shares of its Common...


Sep 02, 2014, 08:00 ET Oncothyreon to Present at Rodman & Renshaw Global Investment Conference

SEATTLE, Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive...


Aug 11, 2014, 16:06 ET Oncothyreon Reports Second Quarter 2014 Financial Results

Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported...


Aug 11, 2014, 16:02 ET Oncothyreon Announces Acquisition of Alpine Biosciences

Oncothyreon to Leverage Alpine's Protocell Technology to Enable Targeted Delivery of Molecular Therapeutics for Serious Diseases Company to Hold...


Aug 04, 2014, 08:00 ET Oncothyreon Announces Second Quarter 2014 Financial Results Conference Call

SEATTLE, Aug. 4, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Monday, August 11,...


Jun 02, 2014, 08:00 ET Oncothyreon Announces Presentation of ONT-10 Data at ASCO Annual Meeting

SEATTLE, June 2, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of data from a Phase 1 trial of ONT-10, an...


May 29, 2014, 08:00 ET Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab

SEATTLE, WA and HAMPTON, NJ, May 29, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Celldex Therapeutics, Inc., (NASDAQ: CLDX) today...


May 28, 2014, 16:03 ET Oncothyreon to Present at Jefferies 2014 Global Healthcare Conference

SEATTLE, WA, May 28, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive...


May 01, 2014, 16:05 ET Oncothyreon Reports First Quarter 2014 Financial Results

Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, May 1, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported...


Apr 24, 2014, 08:00 ET Oncothyreon Announces First Quarter 2014 Financial Results Conference Call

SEATTLE, April 24, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, May 1,...


Apr 07, 2014, 06:00 ET Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

SEATTLE, April 7, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced that Merck KGaA, Darmstadt, Germany, has initiated the...


Mar 13, 2014, 16:01 ET Oncothyreon Reports Full Year and Fourth Quarter 2013 Financial Results

Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, March 13, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported...


Mar 06, 2014, 08:00 ET Oncothyreon Announces Full Year and Fourth Quarter 2013 Financial Results Conference Call

SEATTLE, March 6, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, March...


Feb 26, 2014, 08:00 ET Oncothyreon to Present at Cowen and Company 34th Annual Health Care Conference

SEATTLE, WA, Feb. 26, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief...


Feb 20, 2014, 08:00 ET Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer

SEATTLE, WA and BOULDER, CO, Feb. 20, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced...


Feb 03, 2014, 08:00 ET Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer

SEATTLE AND BOULDER, CO, Feb. 3, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the...


Nov 12, 2013, 16:00 ET Oncothyreon Reports Third Quarter 2013 Financial Results

Company to Hold Conference Call at 4:30 p.m. EST Today SEATTLE, WA, Nov. 12, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported...


Nov 08, 2013, 08:00 ET Oncothyreon Announces Presentation of Data from Phase 1Trial of ONT-10

SEATTLE, Nov. 8, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of preliminary results from an ongoing...


Nov 04, 2013, 08:00 ET Oncothyreon Announces Third Quarter 2013 Financial Results Conference Call

SEATTLE, Nov. 4, 2013 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Tuesday, November...


Oct 07, 2013, 08:00 ET Oncothyreon Announces Presentation of Final Results from Phase 1 Trial of ONT-380

SEATTLE, WA, Oct. 7, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of final results from the first Phase 1...


Sep 25, 2013, 06:00 ET Oncothyreon Announces Merck Serono Decision to Continue the Development of Tecemotide in Stage III Non-Small Cell Lung Cancer

SEATTLE, Sept. 25, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced that Merck Serono, the biopharmaceutical division of Merck...


Sep 06, 2013, 08:00 ET Oncothyreon Announces Appointment of Ted W. Love, M.D. to Board of Directors

SEATTLE, Sept. 6, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the appointment of Ted W. Love, M.D., to its board of...


Sep 03, 2013, 08:05 ET Oncothyreon Announces Initiation of Phase 1 Trial of ONT-380 in Combination with Trastuzumab in Patients with Brain Metastases from HER2+ Breast Cancer

SEATTLE, WA, Sept. 3, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the initiation of an investigator-sponsored trial of...


Sep 03, 2013, 08:00 ET Oncothyreon Announces Presentations at Upcoming Investment Conferences in September

SEATTLE, Sept. 3, 2013 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive...